Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs

Pharmacology and Therapeutics

Volumn 162, Issue , 2016, Pages 69-85

  Jackson, Rebecca A ^a   Chen, Ee Sin ^a,b,c,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Epigenetics; Genomics; High throughput screening; Signaling networks; Synthetic lethality

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; ATM PROTEIN; CISPLATIN; CRISPR ASSOCIATED PROTEIN; CYTOTOXIC AGENT; DNA; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; EZH2 INHIBITOR; GLUCOSE; GLUTAMINE; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; HYPOXIA INDUCIBLE FACTOR; MITOMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PANOBINOSTAT; PLATINUM DERIVATIVE; PROTEIN; PROTEIN INHIBITOR; PROTEIN P53; RAS PROTEIN; ROMIDEPSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; VORINOSTAT;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL AGING; CELL DEATH; CELL VIABILITY; CLINICAL ASSESSMENT; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; DNA REPLICATION; DRUG EFFICACY; EPIGENETICS; EXCISION REPAIR; GLYCOLYSIS; HIGH THROUGHPUT SCREENING; HUMAN; LETHALITY; MEIOTIC RECOMBINATION; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SYNTHESIS; PROTEIN TARGETING; RNA INTERFERENCE; ANIMAL; GENETIC EPIGENESIS; GENETICS; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA REPAIR; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS;

EID: 84958559371     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.01.014     Document Type: Review

References (228)

1. American Cancer Society Cancer Facts and Figs. 2015. 2015 American Cancer Society Atlanta
2. M. Aarts, I. Bajrami, M.T. Herrera-Abreu, R. Elliott, R. Brough, A. Ashworth, and et al. Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways Mol Cancer Ther 14 2015 865 876
3. H. Al-Ahmadie, G. Iyer, M. Hohl, S. Asthana, A. Inagaki, N. Schultz, and et al. Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy Cancer Discov 4 2014 1014 1021
4. S. Al-Harbi, G.S. Choudhary, J.S. Ebron, B.T. Hill, N. Vivekanathan, A.H. Ting, and et al. miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies Mol Cancer 14 2015 185
5. A. Ashworth, C.J. Lord, and J.S. Reis-Filho Genetic interactions in cancer progression and treatment Cell 145 2011 30 38
6. M.W. Audeh, J. Carmichael, R.T. Penson, M. Friedlander, B. Powell, K.M. Bell-McGuinn, and et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial Lancet 376 2010 245 251
7. C. Babij, Y. Zhang, R.J. Kurzeja, A. Munzli, A. Shehabeldin, M. Fernando, and et al. STK33 kinase activity is nonessential in KRAS-dependent cancer cells Cancer Res 71 2011 5818 5826
8. O. Babur, M. Gonen, B.A. Aksoy, N. Schultz, G. Ciriello, C. Sander, and et al. Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations Genome Biol 16 2015 45
9. R. Bajpai, S.M. Matulis, C. Wei, A.K. Nooka, H.E. Von Hollen, S. Lonial, and et al. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax Oncogene 2015 10.1038/onc.2015.464
10. A.A. Bakkar, H. Wallerand, F. Radvanyi, J.B. Lahaye, S. Pissard, L. Lecerf, and et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder Cancer Res 63 2003 8108 8112
11. C.J. Bakkenist, and M.B. Kastan Chromatin perturbations during the DNA damage response in higher eukaryotes DNA Repair (Amst) 36 2015 8 12
12. D.A. Barbie, P. Tamayo, J.S. Boehm, S.Y. Kim, S.E. Moody, I.F. Dunn, and et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 Nature 462 2009 108 112
13. R. Barrangou, A. Birmingham, S. Wiemann, R.L. Beijersbergen, V. Hornung, and A. Smith Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference Nucleic Acids Res 43 2015 3407 3419
14. A. Baryshnikova, M. Costanzo, Y. Kim, H. Ding, J. Koh, K. Toufighi, and et al. Quantitative analysis of fitness and genetic interactions in yeast on a genome scale Nat Methods 7 2010 1017 1024
15. H. Beck, V. Nahse-Kumpf, M.S. Larsen, K.A. O'Hanlon, S. Patzke, C. Holmberg, and et al. Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption Mol Cell Biol 32 2012 4226 4236
16. K. Bensaad, and A.L. Harris Cancer metabolism as a therapeutic target: metabolic synthetic lethality Oncology (Williston Park) 27 467 2013 (473-464)
17. B.G. Bitler, K.M. Aird, A. Garipov, H. Li, M. Amatangelo, A.V. Kossenkov, and et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers Nat Med 21 2015 231 238
18. B.G. Bitler, N. Fatkhutdinov, and R. Zhang Potential therapeutic targets in ARID1A-mutated cancers Expert Opin Ther Targets 1-4 2015
19. V. Boersma, N. Moatti, S. Segura-Bayona, M.H. Peuscher, J. van der Torre, B.A. Wevers, and et al. MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5' end resection Nature 521 2015 537 540
20. D. Botstein, S.A. Chervitz, and J.M. Cherry Yeast as a model organism Science 277 1997 1259 1260
21. R. Brown, E. Curry, L. Magnani, C.S. Wilhelm-Benartzi, and J. Borley Poised epigenetic states and acquired drug resistance in cancer Nat Rev Cancer 14 2014 747 753
22. H.E. Bryant, N. Schultz, H.D. Thomas, K.M. Parker, D. Flower, E. Lopez, and et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 2005 913 917
23. S.F. Bunting, E. Callen, N. Wong, H.T. Chen, F. Polato, A. Gunn, and et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks Cell 141 2010 243 254
24. D. Canaani Application of the concept synthetic lethality toward anticancer therapy: A promise fulfilled? Cancer Lett 352 2014 59 65
25. D. Cappellen, C. De Oliveira, D. Ricol, S. de Medina, J. Bourdin, X. Sastre-Garau, and et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas Nat Genet 23 1999 18 20
26. A.M. Carrillo, M. Hicks, D. Khabele, and C.M. Eischen Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells Mol Cancer Res 13 2015 1197 1205
27. C. Carvalho, R.X. Santos, S. Cardoso, S. Correia, P.J. Oliveira, M.S. Santos, and et al. Doxorubicin: The good, the bad and the ugly effect Curr Med Chem 16 2009 3267 3285
28. R. Ceccaldi, J.C. Liu, R. Amunugama, I. Hajdu, B. Primack, M.I. Petalcorin, and et al. Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair Nature 518 2015 258 262
29. R. Ceccaldi, B. Rondinelli, and A.D. D'Andrea Repair Pathway Choices and Consequences at the Double-Strand Break Trends Cell Biol 26 2016 52 64
30. S. Cermelli, I.S. Jang, B. Bernard, and C. Grandori Synthetic lethal screens as a means to understand and treat MYC-driven cancers Cold Spring Harb Perspect Med 4 2014
31. D.A. Chan, P.D. Sutphin, P. Nguyen, S. Turcotte, E.W. Lai, A. Banh, and et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality Sci Transl Med 3 2011 (94ra70)
32. Y.H. Cho, L.E. McCullough, M.D. Gammon, H.C. Wu, Y.J. Zhang, Q. Wang, and et al. Promoter Hypermethylation in White Blood Cell DNA and Breast Cancer Risk J Cancer 6 2015 819 824
33. G.S. Choudhary, S. Al-Harbi, S. Mazumder, B.T. Hill, M.R. Smith, J. Bodo, and et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies Cell Death Dis 6 2015 e1593
34. S. Choudhury, V.K. Kolukula, A. Preet, C. Albanese, and M.L. Avantaggiati Dissecting the pathways that destabilize mutant p53: The proteasome or autophagy? Cell Cycle 12 2013 1022 1029
35. A. Ciccia, and S.J. Elledge The DNA damage response: making it safe to play with knives Mol Cell 40 2010 179 204
36. G. Ciriello, E. Cerami, C. Sander, and N. Schultz Mutual exclusivity analysis identifies oncogenic network modules Genome Res 22 2012 398 406
37. J. Cisowski, V.I. Sayin, M. Liu, C. Karlsson, and M.O. Bergo Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF Oncogene 2015 10.1038/onc.2015.186
38. K.A. Cole, J. Huggins, M. Laquaglia, C.E. Hulderman, M.R. Russell, K. Bosse, and et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma Proc Natl Acad Sci U S A 108 2011 3336 3341
39. L. Cong, F.A. Ran, D. Cox, S. Lin, R. Barretto, N. Habib, and et al. Multiplex genome engineering using CRISPR/Cas systems Science 339 2013 819 823
40. L. Conradt, A. Henrich, M. Wirth, M. Reichert, M. Lesina, H. Algul, and et al. Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death Int J Cancer 132 2013 2248 2257
41. M. Costanzo, A. Baryshnikova, J. Bellay, Y. Kim, E.D. Spear, C.S. Sevier, and et al. The genetic landscape of a cell Science 327 2010 425 431
42. F. Cottini, T. Hideshima, R. Suzuki, Y.T. Tai, G. Bianchini, P.G. Richardson, and et al. Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma Cancer Discov 5 2015 972 987
43. A.D. Cox, S.W. Fesik, A.C. Kimmelman, J. Luo, and C.J. Der Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov 13 2014 828 851
44. C.V. Dang, J.W. Kim, P. Gao, and J. Yustein The interplay between MYC and HIF in cancer Nat Rev Cancer 8 2008 51 56
45. S.B. De Lorenzo, A.G. Patel, R.M. Hurley, and S.H. Kaufmann The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells Front Oncol 3 2013 228
46. A.J. Deans, and S.C. West DNA interstrand crosslink repair and cancer Nat Rev Cancer 11 2011 467 480
47. K.J. Dedes, D. Wetterskog, A.M. Mendes-Pereira, R. Natrajan, M.B. Lambros, F.C. Geyer, and et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors Sci Transl Med 2 2010 (53ra75)
48. M.K. DeGorter, C.Q. Xia, J.J. Yang, and R.B. Kim Drug transporters in drug efficacy and toxicity Annu Rev Pharmacol Toxicol 52 2012 249 273
49. R. Deshpande, M.K. Asiedu, M. Klebig, S. Sutor, E. Kuzmin, J. Nelson, and et al. A comparative genomic approach for identifying synthetic lethal interactions in human cancer Cancer Res 73 2013 6128 6136
50. D. Deutscher, I. Meilijson, M. Kupiec, and E. Ruppin Multiple knockout analysis of genetic robustness in the yeast metabolic network Nat Genet 38 2006 993 998
51. M.R. Domingo-Sananes, O. Kapuy, T. Hunt, and B. Novak Switches and latches: A biochemical tug-of-war between the kinases and phosphatases that control mitosis Philos Trans R Soc Lond B Biol Sci 366 2011 3584 3594
52. M. Dorel, E. Barillot, A. Zinovyev, and I. Kuperstein Network-based approaches for drug response prediction and targeted therapy development in cancer Biochem Biophys Res Commun 464 2015 386 391
53. J.R. Dorr, Y. Yu, M. Milanovic, G. Beuster, C. Zasada, J.H. Dabritz, and et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy Nature 501 2013 421 425
54. J.Y. Douillard, G. Ostoros, M. Cobo, T. Ciuleanu, R. McCormack, A. Webster, and et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: A phase-IV, open-label, single-Arm study Br J Cancer 110 2014 55 62
55. J. Downward RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize? Clin Cancer Res 21 2015 1802 1809
56. A. Eijkelenboom, and B.M. Burgering FOXOs: signalling integrators for homeostasis maintenance Nat Rev Mol Cell Biol 14 2013 83 97
57. B.M. Emerling, J.B. Hurov, G. Poulogiannis, K.S. Tsukazawa, R. Choo-Wing, G.M. Wulf, and et al. Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors Cell 155 2013 844 857
58. M.T. Esposito, L. Zhao, T.K. Fung, J.K. Rane, A. Wilson, N. Martin, and et al. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors Nat Med 21 2015 1481 1490
59. D. Etemadmoghadam, B.A. Weir, G. Au-Yeung, K. Alsop, G. Mitchell, J. George, and et al. Synthetic lethality between CCNE1 amplification and loss of BRCA1 Proc Natl Acad Sci U S A 110 2013 19489 19494
60. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, T.B. Richardson, and et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
61. C. Feng, Y. Liu, H. Su, H. Wang, J. Birchler, and F. Han Recent advances in plant centromere biology Sci China Life Sci 58 2015 240 245
62. Z. Feng, S.P. Scott, W. Bussen, G.G. Sharma, G. Guo, T.K. Pandita, and et al. Rad52 inactivation is synthetically lethal with BRCA2 deficiency Proc Natl Acad Sci U S A 108 2011 686 691
63. G.M. Findlay, E.A. Boyle, R.J. Hause, J.C. Klein, and J. Shendure Saturation editing of genomic regions by multiplex homology-directed repair Nature 513 2014 120 123
64. C. Frezza, L. Zheng, O. Folger, K.N. Rajagopalan, E.D. MacKenzie, L. Jerby, and et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase Nature 477 2011 225 228
65. Y. Fu, J.D. Sander, D. Reyon, V.M. Cascio, and J.K. Joung Improving CRISPR-Cas nuclease specificity using truncated guide RNAs Nat Biotechnol 32 2014 279 284
66. B. Furnari, N. Rhind, and P. Russell Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase Science 277 1997 1495 1497
67. M.A. Gadhikar, M.R. Sciuto, M.V. Alves, C.R. Pickering, A.A. Osman, D.M. Neskey, and et al. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53 Mol Cancer Ther 12 2013 1860 1873
68. J.R. Gnarra, K. Tory, Y. Weng, L. Schmidt, M.H. Wei, H. Li, and et al. Mutations of the VHL tumour suppressor gene in renal carcinoma Nat Genet 7 1994 85 90
69. T. Golan, E.Z. Khvalevsky, A. Hubert, R.M. Gabai, N. Hen, A. Segal, and et al. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients Oncotarget 6 2015 24560 24570
70. O. Guell, F. Sagues, and M.A. Serrano Essential plasticity and redundancy of metabolism unveiled by synthetic lethality analysis PLoS Comput Biol 10 2014 e1003637
71. J. Guo, H. Liu, and J. Zheng SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets Nucleic Acids Res 44 2016 D1011 D1017
72. K. Ha, W. Fiskus, D.S. Choi, S. Bhaskara, L. Cerchietti, S.G. Devaraj, and et al. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells Oncotarget 5 2014 5637 5650
73. S. Hacker, S. Karl, I. Mader, S. Cristofanon, T. Schweitzer, J. Krauss, and et al. Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation Oncogene 30 2011 2275 2281
74. J.J. Haddad Oxygen-sensing mechanisms and the regulation of redox-responsive transcription factors in development and pathophysiology Respir Res 3 2002 26
75. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
76. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: The next generation Cell 144 2011 646 674
77. L. Hao, Q. He, Z. Wang, M. Craven, M.A. Newton, and P. Ahlquist Limited agreement of independent RNAi screens for virus-required host genes owes more to false-negative than false-positive factors PLoS Comput Biol 9 2013 e1003235
78. C.J. Harris, R.D. Hill, D.W. Sheppard, M.J. Slater, and P.F. Stouten The design and application of target-focused compound libraries Comb Chem High Throughput Screen 14 2011 521 531
79. L.H. Hartwell, P. Szankasi, C.J. Roberts, A.W. Murray, and S.H. Friend Integrating genetic approaches into the discovery of anticancer drugs Science 278 1997 1064 1068
80. X. He, Z. Zhu, C. Johnson, J. Stoops, A.E. Eaker, W. Bowen, and et al. PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma Cancer Res 68 2008 5591 5598
81. U. Heinicke, and S. Fulda Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA Cancer Lett 351 2014 50 58
82. T. Helleday, H.E. Bryant, and N. Schultz Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy Cell Cycle 4 2005 1176 1178
83. C.T. Hensley, A.T. Wasti, and R.J. DeBerardinis Glutamine and cancer: cell biology, physiology, and clinical opportunities J Clin Invest 123 2013 3678 3684
84. A. Herrero, A. Pinto, P. Colon-Bolea, B. Casar, M. Jones, L. Agudo-Ibanez, and et al. Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes Cancer Cell 28 2015 170 182
85. H. Hirai, Y. Iwasawa, M. Okada, T. Arai, T. Nishibata, M. Kobayashi, and et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents Mol Cancer Ther 8 2009 2992 3000
86. A. Hirayama, K. Kami, M. Sugimoto, M. Sugawara, N. Toki, H. Onozuka, and et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry Cancer Res 69 2009 4918 4925
87. S. Hocke, Y. Guo, A. Job, M. Orth, A. Ziesch, K. Lauber, and et al. A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers Oncotarget 2016 10.18632/oncotarget.6857
88. M.O. Hottiger Poly(ADP-ribose) polymerase inhibitor therapeutic effect: Are we just scratching the surface? Expert Opin Ther Targets 19 2015 1149 1152
89. S. Hu, L. Yu, Z. Li, Y. Shen, J. Wang, J. Cai, and et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo Cancer Biol Ther 10 2010 788 795
90. P. Jaakkola, D.R. Mole, Y.M. Tian, M.I. Wilson, J. Gielbert, S.J. Gaskell, and et al. Targeting of HIF-Alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation Science 292 2001 468 472
91. J.R. Jackson, A. Gilmartin, C. Imburgia, J.D. Winkler, L.A. Marshall, and A. Roshak An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage Cancer Res 60 2000 566 572
92. H.H. Jeng, L.J. Taylor, and D. Bar-Sagi Sos-mediated cross-Activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis Nat Commun 3 2012 1168
93. L. Jerby-Arnon, N. Pfetzer, Y.Y. Waldman, L. McGarry, D. James, E. Shanks, and et al. Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality Cell 158 2014 1199 1209
94. H. Jiang, H.C. Reinhardt, J. Bartkova, J. Tommiska, C. Blomqvist, H. Nevanlinna, and et al. The combined status of ATM and p53 link tumor development with therapeutic response Genes Dev 23 2009 1895 1909
95. U. Jo, and H. Kim Exploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer Therapy Mol Cells 38 2015 669 676
96. S. Jones, T.L. Wang, M. Shih Ie, T.L. Mao, K. Nakayama, R. Roden, and et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma Science 330 2010 228 231
97. A.D. Kacsinta, and S.F. Dowdy Current views on inducing synthetic lethal RNAi responses in the treatment of cancer Expert Opin Biol Ther 1-12 2015
98. C. Kandoth, M.D. McLellan, F. Vandin, K. Ye, B. Niu, C. Lu, and et al. Mutational landscape and significance across 12 major cancer types Nature 502 2013 333 339
99. W.J. Keune, A.H. Sims, D.R. Jones, Y. Bultsma, J.T. Lynch, K. Jirstrom, and et al. Low PIP4K2B expression in human breast tumors correlates with reduced patient survival: A role for PIP4K2B in the regulation of E-cadherin expression Cancer Res 73 2013 6913 6925
100. M.S. Kim, M. Blake, J.H. Baek, G. Kohlhagen, Y. Pommier, and F. Carrier Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA Cancer Res 63 2003 7291 7300
101. S. Kim, Y. Kim, J. Lee, and J. Chung Regulation of FOXO1 by TAK1-Nemo-like kinase pathway J Biol Chem 285 2010 8122 8129
102. J. Kim, and A.C. Tan BiNGS!SL-seq: A bioinformatics pipeline for the analysis and interpretation of deep sequencing genome-wide synthetic lethal screen Methods Mol Biol 802 2012 389 398
103. H. Koike-Yusa, Y. Li, E.P. Tan, C. Velasco-Herrera Mdel, and K. Yusa Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library Nat Biotechnol 32 2014 267 273
104. R. Koppensteiner, E.P. Samartzis, A. Noske, A. von Teichman, I. Dedes, M. Gwerder, and et al. Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro PLoS One 9 2014 e100041
105. J.E. Krebs DNA replication, repair and recombination 2nd ed. 2011 Jones and Bartlett Publishers Sudbury, Massachusetts
106. M.S. Kumar, D.C. Hancock, M. Molina-Arcas, M. Steckel, P. East, M. Diefenbacher, and et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer Cell 149 2012 642 655
107. M. Kwok, N. Davies, A. Agathanggelou, E. Smith, E. Petermann, E. Yates, and et al. Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway Lancet 385 Suppl. 1 2015 S58
108. G. Lahav Oscillations by the p53-Mdm2 feedback loop Adv Exp Med Biol 641 2008 28 38
109. H. Ledford CRISPR, the disruptor Nature 522 2015 20 24
110. Y.K. Lee, N.H. Park, and H. Lee Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers Exp Mol Med 47 2015 e195
111. M.J. Lee, A.S. Ye, A.K. Gardino, A.M. Heijink, P.K. Sorger, G. MacBeath, and et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks Cell 149 2012 780 794
112. M.D. Leiserson, H.T. Wu, F. Vandin, and B.J. Raphael CoMEt: A statistical approach to identify combinations of mutually exclusive alterations in cancer Genome Biol 16 2015 160
113. A.J. Levine, and A.M. Puzio-Kuter The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes Science 330 2010 1340 1344
114. D. Li, N.D. Marchenko, and U.M. Moll SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis Cell Death Differ 18 2011 1904 1913
115. P. Liberali, B. Snijder, and L. Pelkmans Single-cell and multivariate approaches in genetic perturbation screens Nat Rev Genet 16 2015 18 32
116. M.R. Lieber The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway Annu Rev Biochem 79 2010 181 211
117. S.M. Lim, K.D. Westover, S.B. Ficarro, R.A. Harrison, H.G. Choi, M.E. Pacold, and et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor Angew Chem Int Ed Engl 53 2014 199 204
118. Y.C. Lin, Y.C. Lin, J.Y. Shih, W.J. Huang, S.W. Chao, Y.L. Chang, and et al. DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers Clin Cancer Res 21 2015 428 438
119. J. Liu, and W.D. Heyer Who's who in human recombination: BRCA2 and RAD52 Proc Natl Acad Sci U S A 108 2011 441 442
120. E.Y. Liu, N. Xu, J. O'Prey, L.Y. Lao, S. Joshi, J.S. Long, and et al. Loss of autophagy causes a synthetic lethal deficiency in DNA repair Proc Natl Acad Sci U S A 112 2015 773 778
121. J.W. Locasale, A.R. Grassian, T. Melman, C.A. Lyssiotis, K.R. Mattaini, A.J. Bass, and et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis Nat Genet 43 2011 869 874
122. B.H. Lok, A.C. Carley, B. Tchang, and S.N. Powell RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination Oncogene 32 2013 3552 3558
123. J. Luo, M.J. Emanuele, D. Li, C.J. Creighton, M.R. Schlabach, T.F. Westbrook, and et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene Cell 137 2009 835 848
124. T. Luo, K. Masson, J.D. Jaffe, W. Silkworth, N.T. Ross, C.A. Scherer, and et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability Proc Natl Acad Sci U S A 109 2012 2860 2865
125. B. Mair, S. Kubicek, and S.M. Nijman Exploiting epigenetic vulnerabilities for cancer therapeutics Trends Pharmacol Sci 35 2014 136 145
126. I.W. Mak, N. Evaniew, and M. Ghert Lost in translation: Animal models and clinical trials in cancer treatment Am J Transl Res 6 2014 114 118
127. P. Mali, J. Aach, P.B. Stranges, K.M. Esvelt, M. Moosburner, S. Kosuri, and et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering Nat Biotechnol 31 2013 833 838
128. P. Mali, L. Yang, K.M. Esvelt, J. Aach, M. Guell, J.E. DiCarlo, and et al. RNA-guided human genome engineering via Cas9 Science 339 2013 823 826
129. P.A. Mateos-Gomez, F. Gong, N. Nair, K.M. Miller, E. Lazzerini-Denchi, and A. Sfeir Mammalian polymerase theta promotes alternative NHEJ and suppresses recombination Nature 518 2015 254 257
130. N. McCabe, N.C. Turner, C.J. Lord, K. Kluzek, A. Bialkowska, S. Swift, and et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition Cancer Res 66 2006 8109 8115
131. H.R. McMurray, E.R. Sampson, G. Compitello, C. Kinsey, L. Newman, B. Smith, and et al. Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype Nature 453 2008 1112 1116
132. W. Megchelenbrink, R. Katzir, X. Lu, E. Ruppin, and R.A. Notebaart Synthetic dosage lethality in the human metabolic network is highly predictive of tumor growth and cancer patient survival Proc Natl Acad Sci U S A 112 2015 12217 12222
133. A.M. Mendes-Pereira, C.J. Lord, and A. Ashworth NLK is a novel therapeutic target for PTEN deficient tumour cells PLoS One 7 2012 e47249
134. A.M. Mendes-Pereira, S.A. Martin, R. Brough, A. McCarthy, J.R. Taylor, J.S. Kim, and et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors EMBO Mol Med 1 2009 315 322
135. J.A. Menendez, C. Oliveras-Ferraros, S. Cufi, B. Corominas-Faja, J. Joven, B. Martin-Castillo, and et al. Metformin is synthetically lethal with glucose withdrawal in cancer cells Cell Cycle 11 2012 2782 2792
136. T.R. Mereniuk, M.A. El Gendy, A.M. Mendes-Pereira, C.J. Lord, S. Ghosh, E. Foley, and et al. Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase Mol Cancer Ther 12 2013 2135 2144
137. N. Mohell, J. Alfredsson, A. Fransson, M. Uustalu, S. Bystrom, J. Gullbo, and et al. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells Cell Death Dis 6 2015 e1794
138. K.N. Mohni, P.S. Thompson, J.W. Luzwick, G.G. Glick, C.S. Pendleton, B.D. Lehmann, and et al. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments PLoS One 10 2015 e0125482
139. G.L. Moldovan, and A.D. D'Andrea How the fanconi anemia pathway guards the genome Annu Rev Genet 43 2009 223 249
140. A.A. Morales, M. Kurtoglu, S.M. Matulis, J. Liu, D. Siefker, D.M. Gutman, and et al. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells Blood 118 2011 1329 1339
141. S. Morandell, H.C. Reinhardt, I.G. Cannell, J.S. Kim, D.M. Ruf, T. Mitra, and et al. A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo Cell Rep 5 2013 868 877
142. P.A. Muller, A.G. Trinidad, P.T. Caswell, J.C. Norman, and K.H. Vousden Mutant p53 regulates Dicer through p63-dependent and -independent mechanisms to promote an invasive phenotype J Biol Chem 289 2014 122 132
143. T.T.T. Nguyen, J.K.K. Chua, S. S.K., S.H. Koo, J.Y. Yee, E.G. Yang, and et al. Predicting chemotherapeutic drug combinations through gene network profiling Sci Rep 6 2016 18658
144. T.T. Nguyen, J.S. Lim, R.M. Tang, L. Zhang, and E.S. Chen Fitness profiling links topoisomerase II regulation of centromeric integrity to doxorubicin resistance in fission yeast Sci Rep 5 2015 8400
145. S.M. Nijman Synthetic lethality: general principles, utility and detection using genetic screens in human cells FEBS Lett 585 2011 1 6
146. K. Obermeier, J. Sachsenweger, T.W. Friedl, H. Pospiech, R. Winqvist, and L. Wiesmuller Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients Oncogene 2015 10.1038/onc.2015.448
147. J.M. Ostrem, U. Peters, M.L. Sos, J.A. Wells, and K.M. Shokat K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions Nature 503 2013 548 551
148. J.M. Paul, S.D. Templeton, A. Baharani, A. Freywald, and F.J. Vizeacoumar Building high-resolution synthetic lethal networks: A 'Google map' of the cancer cell Trends Mol Med 20 2014 704 715
149. T. Pawson, and N. Warner Oncogenic re-wiring of cellular signaling pathways Oncogene 26 2007 1268 1275
150. C.Y. Peng, P.R. Graves, R.S. Thoma, Z. Wu, A.S. Shaw, and H. Piwnica-Worms Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216 Science 277 1997 1501 1505
151. S.B. Peng, J.R. Henry, M.D. Kaufman, W.P. Lu, B.D. Smith, S. Vogeti, and et al. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers Cancer Cell 28 2015 384 398
152. P.A. Perez-Mancera, A.R. Young, and M. Narita Inside and out: The activities of senescence in cancer Nat Rev Cancer 14 2014 547 558
153. C.M. Perou, T. Sorlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, and et al. Molecular portraits of human breast tumours Nature 406 2000 747 752
154. R. Possemato, K.M. Marks, Y.D. Shaul, M.E. Pacold, D. Kim, K. Birsoy, and et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer Nature 476 2011 346 350
155. A. Pratapa, S. Balachandran, and K. Raman Fast-SL: An efficient algorithm to identify synthetic lethal sets in metabolic networks Bioinformatics 31 2015 3299 3305
156. P. Raha, S. Thomas, K.T. Thurn, J. Park, and P.N. Munster Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression Breast Cancer Res 17 2015 26
157. L. Raj, T. Ide, A.U. Gurkar, M. Foley, M. Schenone, X. Li, and et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS Nature 475 2011 231 234
158. H.C. Reinhardt, A.S. Aslanian, J.A. Lees, and M.B. Yaffe p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage Cancer Cell 11 2007 175 189
159. H.C. Reinhardt, H. Jiang, M.T. Hemann, and M.B. Yaffe Exploiting synthetic lethal interactions for targeted cancer therapy Cell Cycle 8 2009 3112 3119
160. E. Remy, S. Rebouissou, C. Chaouiya, A. Zinovyev, F. Radvanyi, and L. Calzone A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis Cancer Res 75 2015 4042 4052
161. A. Roguev, S. Bandyopadhyay, M. Zofall, K. Zhang, T. Fischer, S.R. Collins, and et al. Conservation and rewiring of functional modules revealed by an epistasis map in fission yeast Science 322 2008 405 410
162. T. Rolland, M. Tasan, B. Charloteaux, S.J. Pevzner, Q. Zhong, N. Sahni, and et al. A proteome-scale map of the human interactome network Cell 159 2014 1212 1226
163. G.J. Sabnis, O. Goloubeva, S. Chumsri, N. Nguyen, S. Sukumar, and A.M. Brodie Functional activation of the estrogen receptor-Alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole Cancer Res 71 2011 1893 1903
164. B.V. Sajesh, M. Bailey, Z. Lichtensztejn, P. Hieter, and K.J. McManus Synthetic lethal targeting of superoxide dismutase 1 selectively kills RAD54B-deficient colorectal cancer cells Genetics 195 2013 757 767
165. B.V. Sajesh, and K.J. McManus Targeting SOD1 induces synthetic lethal killing in BLM- and CHEK2-deficient colorectal cancer cells Oncotarget 6 2015 27907 27922
166. B. Samarasinghe The Hallmarks of Cancer 9: Reprogramming Energy Metabolism Vol. 2016 2014 Scientific American
167. Y. Sanchez, C. Wong, R.S. Thoma, R. Richman, Z. Wu, H. Piwnica-Worms, and et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25 Science 277 1997 1497 1501
168. F.J. Sanchez-Rivera, and T. Jacks Applications of the CRISPR-Cas9 system in cancer biology Nat Rev Cancer 15 2015 387 395
169. J.D. Sander, and J.K. Joung CRISPR-Cas systems for editing, regulating and targeting genomes Nat Biotechnol 32 2014 347 355
170. C. Scholl, S. Frohling, I.F. Dunn, A.C. Schinzel, D.A. Barbie, S.Y. Kim, and et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells Cell 137 2009 821 834
171. R.A. Schwab, J. Nieminuszczy, F. Shah, J. Langton, D. Lopez Martinez, C.C. Liang, and et al. The Fanconi Anemia Pathway Maintains Genome Stability by Coordinating Replication and Transcription Mol Cell 60 2015 351 361
172. S. Sharifpoor, D. van Dyk, M. Costanzo, A. Baryshnikova, H. Friesen, A.C. Douglas, and et al. Functional wiring of the yeast kinome revealed by global analysis of genetic network motifs Genome Res 22 2012 791 801
173. S.V. Sharma, P. Gajowniczek, I.P. Way, D.Y. Lee, J. Jiang, Y. Yuza, and et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes Cancer Cell 10 2006 425 435
174. A. Simons, N. Dafni, I. Dotan, Y. Oron, and D. Canaani Establishment of a chemical synthetic lethality screen in cultured human cells Genome Res 11 2001 266 273
175. K.R. Singleton, T.K. Hinz, E.K. Kleczko, L.A. Marek, J. Kwak, T. Harp, and et al. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC Cancer Res 75 2015 4398 4406
176. C. Sourbier, B.T. Scroggins, R. Ratnayake, T.L. Prince, S. Lee, M.J. Lee, and et al. Englerin A stimulates PKCtheta to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality Cancer Cell 23 2013 228 237
177. D. Sproul, C. Nestor, J. Culley, J.H. Dickson, J.M. Dixon, D.J. Harrison, and et al. Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer Proc Natl Acad Sci U S A 108 2011 4364 4369
178. S. Srihari, J. Singla, L. Wong, and M.A. Ragan Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer Biol Direct 10 2015 57
179. G.C. Stachelek, E. Peterson-Roth, Y. Liu, R.J. Fernandez 3rd, L.R. Pike, J.M. Qian, and et al. YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors Mol Cancer Res 13 2015 1389 1397
180. M. Steckel, M. Molina-Arcas, B. Weigelt, M. Marani, P.H. Warne, H. Kuznetsov, and et al. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies Cell Res 22 2012 1227 1245
181. S. Sudarshan, C. Sourbier, H.S. Kong, K. Block, V.A. Valera Romero, Y. Yang, and et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species Mol Cell Biol 29 2009 4080 4090
182. P.F. Suthers, A. Zomorrodi, and C.D. Maranas Genome-scale gene/reaction essentiality and synthetic lethality analysis Mol Syst Biol 5 2009 301
183. L. Szablewski Expression of glucose transporters in cancers Biochim Biophys Acta 1835 2013 164 169
184. E. Szczurek, and N. Beerenwinkel Modeling mutual exclusivity of cancer mutations PLoS Comput Biol 10 2014 e1003503
185. O. Tacar, P. Sriamornsak, and C.R. Dass Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems J Pharm Pharmacol 65 2013 157 170
186. M.Y. Tang, H. Guo, T.T. Nguyen, L.S. Low, R.A. Jackson, T. Yamada, and et al. Two fission yeast high mobility group box proteins in the maintenance of genomic integrity following doxorubicin insult Gene 562 2015 70 75
187. Z. Tay, R.J. Eng, K. Sajiki, K.K. Lim, M.Y. Tang, M. Yanagida, and et al. Cellular robustness conferred by genetic crosstalk underlies resistance against chemotherapeutic drug doxorubicin in fission yeast PLoS One 8 2013 e55041
188. Z. Tay, S.H. Koo, T.T. Nguyen, T.S. Tan, M.L. Chen, C.F. Chin, and et al. P-glycoprotein and vacuolar ATPase synergistically confer anthracycline resistance to fission yeast and human cells Curr Med Chem 21 2014 251 260
189. J.P. Thiery, H. Acloque, R.Y. Huang, and M.A. Nieto Epithelial-mesenchymal transitions in development and disease Cell 139 2009 871 890
190. A. Thomas, and G. Giaccone Why has active immunotherapy not worked in lung cancer? Ann Oncol 26 2015 2213 2220
191. J.M. Thompson, Q.H. Nguyen, M. Singh, and O.V. Razorenova Approaches to identifying synthetic lethal interactions in cancer Yale J Biol Med 88 2015 145 155
192. C.J. Torrance, V. Agrawal, B. Vogelstein, and K.W. Kinzler Use of isogenic human cancer cells for high-throughput screening and drug discovery Nat Biotechnol 19 2001 940 945
193. L.C. Trotman, A. Alimonti, P.P. Scaglioni, J.A. Koutcher, C. Cordon-Cardo, and P.P. Pandolfi Identification of a tumour suppressor network opposing nuclear Akt function Nature 441 2006 523 527
194. T. Tsuruta, K. Kozaki, A. Uesugi, M. Furuta, A. Hirasawa, I. Imoto, and et al. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer Cancer Res 71 2011 6450 6462
195. S. Turcotte, P.D. Sutphin, and A.J. Giaccia Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: A novel molecule that induces autophagic cell death Autophagy 4 2008 944 946
196. N. Turner, A. Tutt, and A. Ashworth Hallmarks of 'BRCAness' in sporadic cancers Nat Rev Cancer 4 2004 814 819
197. A.N. Tutt, C.J. Lord, N. McCabe, H. Farmer, N. Turner, N.M. Martin, and et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer Cold Spring Harb Symp Quant Biol 70 2005 139 148
198. A. Tutt, M. Robson, J.E. Garber, S.M. Domchek, M.W. Audeh, J.N. Weitzel, and et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial Lancet 376 2010 235 244
199. A.M. Unni, W.W. Lockwood, K. Zejnullahu, S.Q. Lee-Lin, and H. Varmus Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma Elife 4 2015 e06907
200. R. van der Meer, H.Y. Song, S.H. Park, S.A. Abdulkadir, and M. Roh RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition Clin Cancer Res 20 2014 3211 3221
201. B.W. van Rhijn, T.H. van der Kwast, A.N. Vis, W.J. Kirkels, E.R. Boeve, A.C. Jobsis, and et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma Cancer Res 64 2004 1911 1914
202. F.P. Vendetti, A. Lau, S. Schamus, T.P. Conrads, M.J. O'Connor, and C.J. Bakkenist The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo Oncotarget 2015 10.18632/oncotarget.6247
203. B. Viollet, and M. Foretz Revisiting the mechanisms of metformin action in the liver Ann Endocrinol (Paris) 74 2013 123 129
204. B. Vogelstein, N. Papadopoulos, V.E. Velculescu, S. Zhou, L.A. Diaz Jr., and K.W. Kinzler Cancer genome landscapes Science 339 2013 1546 1558
205. J.C. Wang Cellular roles of DNA topoisomerases: A molecular perspective Nat Rev Mol Cell Biol 3 2002 430 440
206. L. Wang, P.J. Hamard, and S.D. Nimer PARP inhibitors: A treatment option for AML? Nat Med 21 2015 1393 1394
207. Y. Wang, V.N. Ngo, M. Marani, Y. Yang, G. Wright, L.M. Staudt, and et al. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells Oncogene 29 2010 4658 4670
208. X. Wang, and R. Simon Identification of potential synthetic lethal genes to p53 using a computational biology approach BMC Med Genomics 6 2013 30
209. R. Watanabe, A. Ui, S. Kanno, H. Ogiwara, T. Nagase, T. Kohno, and et al. SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability Cancer Res 74 2014 2465 2475
210. A.M. Weber, and A.J. Ryan ATM and ATR as therapeutic targets in cancer Pharmacol Ther 149 2015 124 138
211. M. Weiwer, J. Spoonamore, J. Wei, B. Guichard, N.T. Ross, K. Masson, and et al. A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells ACS Med Chem Lett 3 2012 1034 1038
212. K.C. Wiegand, S.P. Shah, O.M. Al-Agha, Y. Zhao, K. Tse, T. Zeng, and et al. ARID1A mutations in endometriosis-Associated ovarian carcinomas N Engl J Med 363 2010 1532 1543
213. A.P. Wiegmans, P.Y. Yap, A. Ward, Y.C. Lim, and K.K. Khanna Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition Mol Cancer Ther 14 2015 2321 2331
214. A.J. Wiggans, G.K. Cass, A. Bryant, T.A. Lawrie, and J. Morrison Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer Cochrane Database Syst Rev 5 2015 CD007929
215. K. Wilhelm, K. Happel, G. Eelen, S. Schoors, M.F. Oellerich, R. Lim, and et al. FOXO1 couples metabolic activity and growth state in the vascular endothelium Nature 529 2016 216 220
216. N.C. Wolff, A. Pavia-Jimenez, V.T. Tcheuyap, S. Alexander, M. Vishwanath, A. Christie, and et al. High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma Oncotarget 6 2015 16951 16962
217. L.D. Wood, D.W. Parsons, S. Jones, J. Lin, T. Sjoblom, R.J. Leary, and et al. The genomic landscapes of human breast and colorectal cancers Science 318 2007 1108 1113
218. W. Wu, and S. Zhao Metabolic changes in cancer: beyond the Warburg effect Acta Biochim Biophys Sin (Shanghai) 45 2013 18 26
219. G. Xu, J.R. Chapman, I. Brandsma, J. Yuan, M. Mistrik, P. Bouwman, and et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition Nature 521 2015 541 544
220. Z. Yang, A. Jones, M. Widschwendter, and A.E. Teschendorff An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer Genome Biol 16 2015 140
221. M.H. Yang, S. Nickerson, E.T. Kim, C. Liot, G. Laurent, R. Spang, and et al. Regulation of RAS oncogenicity by acetylation Proc Natl Acad Sci U S A 109 2012 10843 10848
222. M. Yin, G. Hapke, B. Guo, R.G. Azrak, C. Frank, and Y.M. Rustum The Chk1-Cdc25C regulation is involved in sensitizing A253 cells to a novel topoisomerase I inhibitor BNP1350 by bax gene transfer Oncogene 20 2001 5249 5257
223. D.H. Yu, R.A. Waterland, P. Zhang, D. Schady, M.H. Chen, Y. Guan, and et al. Targeted p16(Ink4a) epimutation causes tumorigenesis and reduces survival in mice J Clin Invest 124 2014 3708 3712
224. N. Zache, J.M. Lambert, K.G. Wiman, and V.J. Bykov PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53 Cell Oncol 30 2008 411 418
225. C. Zeller, W. Dai, N.L. Steele, A. Siddiq, A.J. Walley, C.S. Wilhelm-Benartzi, and et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling Oncogene 31 2012 4567 4576
226. Q. Zhang, S.K. Padi, D.J. Tindall, and B. Guo Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31 Cell Death Dis 5 2014 e1486
227. L. Zhang, H. Quan, S. Wang, X. Li, and X. Che MiR-183 promotes growth of non-small cell lung cancer cells through FoxO1 inhibition Tumour Biol 36 2015 8121 8126
228. F. Zhang, M. Wu, X.J. Li, X.L. Li, C.K. Kwoh, and J. Zheng Predicting essential genes and synthetic lethality via influence propagation in signaling pathways of cancer cell fates J Bioinform Comput Biol 13 2015 1541002